EVX-01

DRUG2 trials

Sponsors

Evaxion A/S, Evaxion Biotech A/S

Conditions

Melanoma Stage IVUnresectable Melanomaunresectable or metastatic melanoma

Phase 2

A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma

Active, not recruitingNCT05309421

Evaxion Biotech A/SMelanoma Stage IV, Unresectable Melanoma

Start: 2022-09-19End: 2026-03-30Updated: 2025-09-22

An open label, single arm trial evaluating the efficacy and safety of EVX-01 in combination with pembrolizumab in checkpoint inhibitor treatment naïve adults with unresectable or metastatic melanoma

CompletedCTIS2024-512393-10-00

Evaxion A/Sunresectable or metastatic melanoma

Start: 2023-03-15End: 2025-09-23Target: 3Updated: 2025-07-25

Related Papers

Abstract 7741: AI-designed personalized neoantigen vaccine, EVX-01, induces durable <i>de novo</i> T-cell responses in advanced melanoma patients

Cancer Research2026-04-03

Abstract 4538: T-cell immunogenicity and biomarker profiling in advanced melanoma patients receiving the personalized vaccine EVX-01 in combination with pembrolizumab

Cancer Research2025-04-21

Immunogenicity of an AI-designed personalized neoantigen vaccine, EVX-01, in combination with anti-PD-1 therapy in patients with metastatic melanoma.

Journal of Clinical Oncology2024-06-015 citations

782-H Effects of an AI generated personalized neopeptide-based immunotherapy, EVX-01, in combination with pembrolizumab in patients with metastatic melanoma: a clinical trial update

2023-10-311 citations

KEYNOTE – D36: Personalized Immunotherapy with a Neoepitope Vaccine, EVX-01 and Pembrolizumab in Advanced Melanoma

Future Oncology2022-09-0123 citations